A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus

Elizabeth R. Allen; Stefanie A. Krumm; Jayna Raghwani; Steinar Halldorsson; Angela Elliott; Victoria A. Graham; Elina Koudriakova; Karl Harlos; Daniel Wright; George M. Warimwe; Benjamin Brennan; Juha T. Huiskonen; Stuart Dowall; Richard M. Elliott; Oliver G. Pybus; Dennis R. Burton; Roger Hewson; Katie J. Doores; Thomas A. Bowden

doi:10.1016/j.celrep.2018.12.001

A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus

Elizabeth R. Allen, Stefanie A. Krumm, Jayna Raghwani, Steinar Halldorsson, Angela Elliott, Victoria A. Graham, Elina Koudriakova, Karl Harlos, Daniel Wright, George M. Warimwe, Benjamin Brennan, Juha T. Huiskonen, Stuart Dowall, Richard M. Elliott, Oliver G. Pybus, Dennis R. Burton, Roger Hewson, Katie J. Doores^*, Thomas A. Bowden

^*Corresponding author for this work

Research & Technical Staff

Research output: Contribution to journal › Article › peer-review

32 Citations (Scopus)

Abstract

Allen et al. reveal a molecular basis of antibody-mediated neutralization of Rift Valley fever virus, an important human and animal pathogen. They isolate and demonstrate the protective efficacy of a monoclonal antibody in a murine model of virus infection, providing a blueprint for rational therapeutic and vaccine design.

Original language	English
Pages (from-to)	3750-3758.e4
Journal	Cell Reports
Volume	25
Issue number	13
DOIs	https://doi.org/10.1016/j.celrep.2018.12.001
Publication status	Published - 26 Dec 2018

Bibliographical note

Funding Information:
We are grateful to the staff of beamlines I03 at Diamond Light Source (proposal mx14744) for assistance with data collection and of the in vivo CL3 facility at Public Health England, Porton Down, for support with the animal model of RVFV. T.A.B. and K.J.D. are supported by the Medical Research Council (MR/L009528/1, MR/K024426/1, and MR/N002091/1) and Wellcome (089026/Z/09/Z to T.A.B.). G.M.W. is supported through an Oak Foundation Fellowship. This study is published with the permission of the Director of the Kenya Medical Research Institute. O.G.P. was funded by the European Research Council under FP7/2007-2013/European Research Council grant agreement 614725-PATHPHYLODYN. S.H. and J.T.H. are supported by European Research Council under the European Union's Horizon 2020 research and innovation program (649053). The Wellcome Centre for Human Genetics is supported by grant 203141/Z/16/Z. E.R.A. is the recipient of a PHE PhD studentship. We are grateful for Christina Corbaci for assistance with graphic design.

Funding Information:
We are grateful to the staff of beamlines I03 at Diamond Light Source (proposal mx14744) for assistance with data collection and of the in vivo CL3 facility at Public Health England, Porton Down, for support with the animal model of RVFV. T.A.B. and K.J.D. are supported by the Medical Research Council ( MR/L009528/1 , MR/K024426/1 , and MR/N002091/1 ) and Wellcome ( 089026/Z/09/Z to T.A.B.). G.M.W. is supported through an Oak Foundation Fellowship. This study is published with the permission of the Director of the Kenya Medical Research Institute. O.G.P. was funded by the European Research Council under FP7/2007-2013 /European Research Council grant agreement 614725-PATHPHYLODYN. S.H. and J.T.H. are supported by European Research Council under the European Union’s Horizon 2020 research and innovation program ( 649053 ). The Wellcome Centre for Human Genetics is supported by grant 203141/Z/16/Z . E.R.A. is the recipient of a PHE PhD studentship. We are grateful for Christina Corbaci for assistance with graphic design.

Publisher Copyright:
© 2018 The Author(s)

Keywords

Rift Valley fever virus
antibody
antiviral
bunyavirus
immune response
neutralization
phlebovirus
structure
vaccine
virus-host interactions

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.celrep.2018.12.001

Cite this

Allen, E. R., Krumm, S. A., Raghwani, J., Halldorsson, S., Elliott, A., Graham, V. A., Koudriakova, E., Harlos, K., Wright, D., Warimwe, G. M., Brennan, B., Huiskonen, J. T., Dowall, S., Elliott, R. M., Pybus, O. G., Burton, D. R., Hewson, R., Doores, K. J., & Bowden, T. A. (2018). A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus. Cell Reports, 25(13), 3750-3758.e4. https://doi.org/10.1016/j.celrep.2018.12.001

@article{31e4a26f291848f99b507c120ba1cbea,

title = "A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus",

abstract = "Allen et al. reveal a molecular basis of antibody-mediated neutralization of Rift Valley fever virus, an important human and animal pathogen. They isolate and demonstrate the protective efficacy of a monoclonal antibody in a murine model of virus infection, providing a blueprint for rational therapeutic and vaccine design.",

keywords = "Rift Valley fever virus, antibody, antiviral, bunyavirus, immune response, neutralization, phlebovirus, structure, vaccine, virus-host interactions",

author = "Allen, {Elizabeth R.} and Krumm, {Stefanie A.} and Jayna Raghwani and Steinar Halldorsson and Angela Elliott and Graham, {Victoria A.} and Elina Koudriakova and Karl Harlos and Daniel Wright and Warimwe, {George M.} and Benjamin Brennan and Huiskonen, {Juha T.} and Stuart Dowall and Elliott, {Richard M.} and Pybus, {Oliver G.} and Burton, {Dennis R.} and Roger Hewson and Doores, {Katie J.} and Bowden, {Thomas A.}",

note = "Funding Information: We are grateful to the staff of beamlines I03 at Diamond Light Source (proposal mx14744) for assistance with data collection and of the in vivo CL3 facility at Public Health England, Porton Down, for support with the animal model of RVFV. T.A.B. and K.J.D. are supported by the Medical Research Council (MR/L009528/1, MR/K024426/1, and MR/N002091/1) and Wellcome (089026/Z/09/Z to T.A.B.). G.M.W. is supported through an Oak Foundation Fellowship. This study is published with the permission of the Director of the Kenya Medical Research Institute. O.G.P. was funded by the European Research Council under FP7/2007-2013/European Research Council grant agreement 614725-PATHPHYLODYN. S.H. and J.T.H. are supported by European Research Council under the European Union's Horizon 2020 research and innovation program (649053). The Wellcome Centre for Human Genetics is supported by grant 203141/Z/16/Z. E.R.A. is the recipient of a PHE PhD studentship. We are grateful for Christina Corbaci for assistance with graphic design. Funding Information: We are grateful to the staff of beamlines I03 at Diamond Light Source (proposal mx14744) for assistance with data collection and of the in vivo CL3 facility at Public Health England, Porton Down, for support with the animal model of RVFV. T.A.B. and K.J.D. are supported by the Medical Research Council ( MR/L009528/1 , MR/K024426/1 , and MR/N002091/1 ) and Wellcome ( 089026/Z/09/Z to T.A.B.). G.M.W. is supported through an Oak Foundation Fellowship. This study is published with the permission of the Director of the Kenya Medical Research Institute. O.G.P. was funded by the European Research Council under FP7/2007-2013 /European Research Council grant agreement 614725-PATHPHYLODYN. S.H. and J.T.H. are supported by European Research Council under the European Union{\textquoteright}s Horizon 2020 research and innovation program ( 649053 ). The Wellcome Centre for Human Genetics is supported by grant 203141/Z/16/Z . E.R.A. is the recipient of a PHE PhD studentship. We are grateful for Christina Corbaci for assistance with graphic design. Publisher Copyright: {\textcopyright} 2018 The Author(s)",

year = "2018",

month = dec,

day = "26",

doi = "10.1016/j.celrep.2018.12.001",

language = "English",

volume = "25",

pages = "3750--3758.e4",

journal = "Cell Reports",

issn = "2211-1247",

publisher = "Cell Press",

number = "13",

}

Allen, ER, Krumm, SA, Raghwani, J, Halldorsson, S, Elliott, A, Graham, VA, Koudriakova, E, Harlos, K, Wright, D, Warimwe, GM, Brennan, B, Huiskonen, JT, Dowall, S, Elliott, RM, Pybus, OG, Burton, DR, Hewson, R, Doores, KJ & Bowden, TA 2018, 'A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus', Cell Reports, vol. 25, no. 13, pp. 3750-3758.e4. https://doi.org/10.1016/j.celrep.2018.12.001

TY - JOUR

T1 - A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus

AU - Allen, Elizabeth R.

AU - Krumm, Stefanie A.

AU - Raghwani, Jayna

AU - Halldorsson, Steinar

AU - Elliott, Angela

AU - Graham, Victoria A.

AU - Koudriakova, Elina

AU - Harlos, Karl

AU - Wright, Daniel

AU - Warimwe, George M.

AU - Brennan, Benjamin

AU - Huiskonen, Juha T.

AU - Dowall, Stuart

AU - Elliott, Richard M.

AU - Pybus, Oliver G.

AU - Burton, Dennis R.

AU - Hewson, Roger

AU - Doores, Katie J.

AU - Bowden, Thomas A.

N1 - Funding Information: We are grateful to the staff of beamlines I03 at Diamond Light Source (proposal mx14744) for assistance with data collection and of the in vivo CL3 facility at Public Health England, Porton Down, for support with the animal model of RVFV. T.A.B. and K.J.D. are supported by the Medical Research Council (MR/L009528/1, MR/K024426/1, and MR/N002091/1) and Wellcome (089026/Z/09/Z to T.A.B.). G.M.W. is supported through an Oak Foundation Fellowship. This study is published with the permission of the Director of the Kenya Medical Research Institute. O.G.P. was funded by the European Research Council under FP7/2007-2013/European Research Council grant agreement 614725-PATHPHYLODYN. S.H. and J.T.H. are supported by European Research Council under the European Union's Horizon 2020 research and innovation program (649053). The Wellcome Centre for Human Genetics is supported by grant 203141/Z/16/Z. E.R.A. is the recipient of a PHE PhD studentship. We are grateful for Christina Corbaci for assistance with graphic design. Funding Information: We are grateful to the staff of beamlines I03 at Diamond Light Source (proposal mx14744) for assistance with data collection and of the in vivo CL3 facility at Public Health England, Porton Down, for support with the animal model of RVFV. T.A.B. and K.J.D. are supported by the Medical Research Council ( MR/L009528/1 , MR/K024426/1 , and MR/N002091/1 ) and Wellcome ( 089026/Z/09/Z to T.A.B.). G.M.W. is supported through an Oak Foundation Fellowship. This study is published with the permission of the Director of the Kenya Medical Research Institute. O.G.P. was funded by the European Research Council under FP7/2007-2013 /European Research Council grant agreement 614725-PATHPHYLODYN. S.H. and J.T.H. are supported by European Research Council under the European Union’s Horizon 2020 research and innovation program ( 649053 ). The Wellcome Centre for Human Genetics is supported by grant 203141/Z/16/Z . E.R.A. is the recipient of a PHE PhD studentship. We are grateful for Christina Corbaci for assistance with graphic design. Publisher Copyright: © 2018 The Author(s)

PY - 2018/12/26

Y1 - 2018/12/26

N2 - Allen et al. reveal a molecular basis of antibody-mediated neutralization of Rift Valley fever virus, an important human and animal pathogen. They isolate and demonstrate the protective efficacy of a monoclonal antibody in a murine model of virus infection, providing a blueprint for rational therapeutic and vaccine design.

AB - Allen et al. reveal a molecular basis of antibody-mediated neutralization of Rift Valley fever virus, an important human and animal pathogen. They isolate and demonstrate the protective efficacy of a monoclonal antibody in a murine model of virus infection, providing a blueprint for rational therapeutic and vaccine design.

KW - Rift Valley fever virus

KW - antibody

KW - antiviral

KW - bunyavirus

KW - immune response

KW - neutralization

KW - phlebovirus

KW - structure

KW - vaccine

KW - virus-host interactions

UR - http://www.scopus.com/inward/record.url?scp=85058422412&partnerID=8YFLogxK

U2 - 10.1016/j.celrep.2018.12.001

DO - 10.1016/j.celrep.2018.12.001

M3 - Article

C2 - 30590046

AN - SCOPUS:85058422412

SN - 2211-1247

VL - 25

SP - 3750-3758.e4

JO - Cell Reports

JF - Cell Reports

IS - 13

ER -

A Protective Monoclonal Antibody Targets a Site of Vulnerability on the Surface of Rift Valley Fever Virus

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this